Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3012% above fair value
$9.37+0.06 (+0.64%)
Close on Nov 13, 2026Market cap $799.39MP/E –Yield –
Monte Rosa Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Monte Rosa Therapeutics's enterprise value was $257.58M on Nov 11, 2026, against $607.85M a year earlier. Over the last 5 years it ranged from $5.64M to $1.37B, with a median of $269.55M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $257.58M | -55.4% |
| 2025 | Dec 31, 2025 | $577.57M | +92.3% |
| 2024 | Dec 31, 2024 | $300.38M | +34.2% |
| 2023 | Dec 29, 2023 | $223.82M | -12.5% |
| 2022 | Dec 30, 2022 | $255.72M | -56.1% |
| 2021 | Dec 31, 2021 | $582.17M | – |
See a number that looks wrong?